ReviewCurrent drug delivery2026
Nano Biomaterials in Drug Delivery and Tissue Engineering.
Review in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of nanotechnology with biomaterials has opened new avenues in drug delivery and tissue engineering, enhancing therapeutic efficacy and patient outcomes. Nano-sized biomaterials (1-100 nm) demonstrate unique properties that improve drug targeting, reduce side effects, and facilitate tissue regeneration. This review highlights the multifunctional applications of nanoparticles, particularly selenium nanoparticles, in cancer therapy and regenerative medicine. By optimizing interactions with biological systems, these advanced materials are poised to revolutionize treatment protocols, offering targeted therapies that combine diagnostics and therapeutics. The potential of nanobiotechnology in clinical applications underscores its critical role in advancing personalized medicine.
Indexed as
Identifiers
41163289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.